Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 2, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofab632
Keywords
COVID-19; cross-sectional; SARS-CoV-2; seroprevalence; vaccines
Categories
Funding
- Public Health Agency of Canada through Canada's COVID-19 Immunity Task Force
- Health Emergencies Program of the World Health Organization
Ask authors/readers for more resources
Population-level immune surveillance, including serosurveys, is crucial for public health decision-making during a pandemic. Serosurveys can provide valuable information on the prevalence of antibodies, distinguish infection and vaccine-induced immune responses, and guide vaccine distribution and booster dose needs.
Population-level immune surveillance, which includes monitoring exposure and assessing vaccine-induced immunity, is a crucial component of public health decision-making during a pandemic. Serosurveys estimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the population played a key role in characterizing SARS-CoV-2 epidemiology during the early phases of the pandemic. Existing serosurveys provide infrastructure to continue immune surveillance but must be adapted to remain relevant in the SARS-CoV-2 vaccine era. Here, we delineate how SARS-CoV-2 serosurveys should be designed to distinguish infection- and vaccine-induced humoral immune responses to efficiently monitor the evolution of the pandemic. We discuss how serosurvey results can inform vaccine distribution to improve allocation efficiency in countries with scarce vaccine supplies and help assess the need for booster doses in countries with substantial vaccine coverage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available